<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2411">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129774</url>
  </required_header>
  <id_info>
    <org_study_id>V123456</org_study_id>
    <nct_id>NCT05129774</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM</brief_title>
  <official_title>Concurrent Chemoradiotherapy Sequenced Radical Surgery for Para-aortic Lymph Node Metastasis of Left-sided Colon and Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In left-sided colon and rectal cancer, the occurrence of synchronous para-aortic lymph node&#xD;
      metastasis is rare, with the incidence of being approximate 1-2%. Currently, there has been&#xD;
      no standard treatment strategy for this situation. The present trial is designed to evaluate&#xD;
      the safety and efficacy of para-aortic lymph node dissection for left-sided colon and rectal&#xD;
      cancer with synchronous para-aortic lymph node metastasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year OS</measure>
    <time_frame>From date of recruitment until the date of death from any cause, assessed up to 5 years</time_frame>
    <description>5-year overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>From date of recruitment until the date of disease recurrece, assessed up to 5 years</time_frame>
    <description>5-year disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LFFS</measure>
    <time_frame>From date of recruitment until the date of para-aortic lymph node recurrence, assessed up to 3 years</time_frame>
    <description>Local failure free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>From date of surgery until the date of 30 days after surgery</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Colorectal Neoplasms Malignant</condition>
  <condition>Lymph Node Excision</condition>
  <condition>Chemoradiotherapy</condition>
  <arm_group>
    <arm_group_label>radical surgery with PALND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>radical surgery without PALND</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical surgery with PALND</intervention_name>
    <description>sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach</description>
    <arm_group_label>radical surgery with PALND</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical surgery without PALND</intervention_name>
    <description>surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND</description>
    <arm_group_label>radical surgery without PALND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age at enrollment is ≥ 18 and ≤ 75 years&#xD;
&#xD;
          -  ECOG PS 0-1&#xD;
&#xD;
          -  histologically confirmed left-sided colon and rectal carcinoma&#xD;
&#xD;
          -  synchronous para-aortic lymph node metastases confirmed by PET-CT, and located below&#xD;
             the level of renal veins and above the bifurcation of iliac artery&#xD;
&#xD;
          -  patients potential to receive surgery and achieve no evidence of disease (NED)&#xD;
&#xD;
          -  able to tolerate surgery&#xD;
&#xD;
          -  providing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  local invasion or distant metastasis other than para-aoritc lymph nodes&#xD;
&#xD;
          -  history of other malignant tumor&#xD;
&#xD;
          -  coupled with severe systematic diseases (recent myocardial infarction, cardiomyopathy,&#xD;
             or acute pulmonary infection)&#xD;
&#xD;
          -  emergency surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Dai, M.D. Ph.D.</last_name>
    <phone>+8618560085117</phone>
    <email>yongdai@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiang Zhang, M.D. Ph.D.</last_name>
    <phone>+8618560089182</phone>
    <email>xiang.zhang02@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiang Zhang</last_name>
      <phone>18560089182</phone>
      <email>xiang.zhang02@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanlei Wang</last_name>
      <phone>18560085128</phone>
      <email>yanleiwang@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

